Brivaracetam: a novel antiepileptic drug for focal-onset seizures
暂无分享,去创建一个
[1] M. Brodie,et al. Brivaracetam-induced elevation of carbamazepine epoxide levels: A post-hoc analysis from the clinical development program , 2018, Epilepsy Research.
[2] J. V. van Gerven,et al. Pharmacological interactions between brivaracetam and ethanol in healthy males , 2017, Journal of psychopharmacology.
[3] C. Wasterlain,et al. Acute and long‐term effects of brivaracetam and brivaracetam–diazepam combinations in an experimental model of status epilepticus , 2017, Epilepsia.
[4] F. Rosenow,et al. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany , 2017, Epilepsia.
[5] M. Bacher,et al. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy—A monocenter survey , 2017, Seizure.
[6] F. Rosenow,et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: A cohort study from two German university hospitals , 2017, Epilepsy & Behavior.
[7] C. Brandt,et al. Health-related quality of life in double-blind Phase III studies of brivaracetam as adjunctive therapy of focal seizures: A pooled, post-hoc analysis , 2017, Epilepsy & Behavior.
[8] J. Wade,et al. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years , 2017, European Journal of Clinical Pharmacology.
[9] M. Wood,et al. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein , 2017, Epilepsia.
[10] Tao Chen,et al. The adverse event profile of brivaracetam: A meta-analysis of randomized controlled trials , 2017, Seizure.
[11] M. Brodie,et al. Pharmacokinetic interaction of brivaracetam on carbamazepine in adult patients with epilepsy, with and without valproate co-administration , 2016, Epilepsy Research.
[12] M. Brodie,et al. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies , 2016, Epilepsy Research.
[13] Francesco Brigo,et al. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs , 2016, Seizure.
[14] Sheridan M. Hoy. Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy , 2016, CNS Drugs.
[15] E. Ben-Menachem,et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies , 2016, Neurology.
[16] V. Biton,et al. Safety and tolerability of adjunctive brivaracetam as intravenous infusion or bolus in patients with epilepsy , 2016, Epilepsia.
[17] P. Kwan,et al. Safety, tolerability, and seizure control during long‐term treatment with adjunctive brivaracetam for partial‐onset seizures , 2016, Epilepsia.
[18] A. Stockis,et al. Bioavailability and bioequivalence comparison of brivaracetam 10, 50, 75, and 100 mg tablets and 100 mg intravenous bolus , 2016, Epilepsia.
[19] A. Scheen,et al. Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis , 2016, Drug Metabolism and Disposition.
[20] M. Silvestrini,et al. Brivaracetam add-on for refractory focal epilepsy , 2016, Neurology.
[21] M. Wood,et al. Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment , 2016, Epilepsia.
[22] F. Andermann,et al. Brivaracetam in Unverricht‐Lundborg disease (EPM1): Results from two randomized, double‐blind, placebo‐controlled studies , 2016, Epilepsia.
[23] Richard E Carson,et al. Brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action , 2016, Epilepsia.
[24] M. Esguerra,et al. Brivaracetam augments short‐term depression and slows vesicle recycling , 2015, Epilepsia.
[25] M. Sperling,et al. A randomized, double‐blind, placebo‐controlled, multicenter, parallel‐group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial‐onset seizures , 2015, Epilepsia.
[26] S. Borghs,et al. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam , 2015, Epilepsy & Behavior.
[27] A. Gambardella,et al. Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures , 2015, Drug design, development and therapy.
[28] C. You,et al. Adjunctive brivaracetam for patients with refractory partial seizures: A meta-analysis of randomized placebo-controlled trials , 2015, Epilepsy Research.
[29] Xuefeng Wang,et al. The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies , 2015, Expert Opinion on Pharmacotherapy.
[30] M. Habibi,et al. Epilepsy and women's health , 2015 .
[31] P. Rolan,et al. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro , 2015, Epilepsy Research.
[32] Philippe Ryvlin,et al. Epilepsy: new advances , 2015, The Lancet.
[33] D. Kaski,et al. Advances in the diagnosis and management of epilepsy in adults , 2015 .
[34] V. André,et al. Brivaracetam Differentially Affects Voltage‐Gated Sodium Currents Without Impairing Sustained Repetitive Firing in Neurons , 2014, CNS neuroscience & therapeutics.
[35] N. Fauchoux,et al. Interaction between brivaracetam (100 mg/day) and a combination oral contraceptive: A randomized, double‐blind, placebo‐controlled study , 2014, Epilepsia.
[36] M. Sperling,et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: A phase III randomized, double‐blind, placebo‐controlled trial , 2014, Epilepsia.
[37] P. Kwan,et al. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: Results of a phase III, double‐blind, randomized, placebo‐controlled, flexible‐dose trial , 2014, Epilepsia.
[38] P. Ryvlin,et al. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: Results from a double‐blind, randomized, placebo‐controlled trial , 2014, Epilepsia.
[39] P. Rolan,et al. Effect of brivaracetam (400 mg/day) on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women , 2013, Journal of clinical pharmacology.
[40] Y. Horsmans,et al. Brivaracetam Disposition in Mild to Severe Hepatic Impairment , 2013, Journal of clinical pharmacology.
[41] W. van Paesschen,et al. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial‐onset seizures: A phase IIb, randomized, controlled trial , 2013, Epilepsia.
[42] J D Norrie,et al. Patterns of treatment response in newly diagnosed epilepsy , 2012, Neurology.
[43] M. Gillard,et al. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. , 2011, European journal of pharmacology.
[44] J. French,et al. Adjunctive brivaracetam for refractory partial-onset seizures , 2010, Neurology.
[45] D. Margineanu,et al. Anti‐convulsive and anti‐epileptic properties of brivaracetam (ucb 34714), a high‐affinity ligand for the synaptic vesicle protein, SV2A , 2008, British journal of pharmacology.
[46] R. Kaminski,et al. SV2A protein is a broad-spectrum anticonvulsant target: Functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy , 2008, Neuropharmacology.
[47] M. Sargentini-Maier,et al. Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects , 2008, Drug Metabolism and Disposition.
[48] D. Truong,et al. Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus , 2007, Journal of Neural Transmission.
[49] P. Rolan,et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. , 2007, British journal of clinical pharmacology.
[50] P. Kwan,et al. Early identification of refractory epilepsy. , 2000, The New England journal of medicine.
[51] M. Feany,et al. The synaptic vesicle protein SV2 is a novel type of transmembrane transporter , 1992, Cell.
[52] R. Scheller,et al. SV2, a brain synaptic vesicle protein homologous to bacterial transporters. , 1992, Science.
[53] S. Irie,et al. Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype. , 2014, Drug metabolism and pharmacokinetics.
[54] P. Rolan,et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. , 2008, British journal of clinical pharmacology.